R. Jayaraman

发表

Arthritis and C-fms for the Treatment of Rheumatoid Sb1578, a Novel Inhibitor of Jak2, Flt3

J. Wood, B. Madan, K. Goh, 2022 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics

Haishan Wang, V. Pilla Reddy, K. Sangthongpitag, 2011, Drug Metabolism and Disposition.

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

J. Wood, B. Goh, W. Yong, 2011, Molecular Cancer Therapeutics.

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

A. Poulsen, A. William, B. Dymock, 2011, Leukemia.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

J. Wood, A. William, B. Dymock, 2012, Leukemia.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder

A. Macone, M. Fiorenza, R. Jayaraman, 2018, Scientific Reports.

Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr

J. Wood, A. Poulsen, A. William, 2012, Journal of medicinal chemistry.

Glycine and alanine dehydrogenase activities are catalyzed by the same protein in Mycobacterium smegmatis: upregulation of both activities under microaerophilic adaptation.

R. Jayaraman, S. Hoffner, J. Toro, 2002, Canadian journal of microbiology.

Nitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy

Anirudh P. Shanbhag, N. Bharatham, R. Jayaraman, 2018, Scientific Reports.

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-

J. Wood, A. Poulsen, Meredith Williams, 2012, Journal of medicinal chemistry.

Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice.

M. Nanjundappa, R. Jayaraman, Avinash S Pawar, 2020, Current drug metabolism.

Nitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy

Anirudh P. Shanbhag, N. Bharatham, R. Jayaraman, 2018, Scientific Reports.

Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase

H. Koike, K. Saigo, M. Tanokura, 1996, Journal of bacteriology.

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

J. Wood, K. Goh, K. Ethirajulu, 2012, Blood Cancer Journal.

Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties

E. Kantharaj, R. Jayaraman, 2011 .

Discovery of Kinase Spectrum Selective Macrocycle

J. Wood, A. Poulsen, Meredith Williams, 2011 .

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho

Anders Poulsen, Stéphanie Blanchard, Harish Nagaraj, 2011, Journal of medicinal chemistry.

Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder

A. Macone, M. Fiorenza, R. Jayaraman, 2018, Scientific Reports.

Chemical Therapeutics VS-5584 , a Novel and Highly Selective PI 3 K / mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2013 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.

Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives

M. Nanjundappa, R. Jayaraman, R. Yedle, 2023, Microbiology spectrum.

nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis

Anders Poulsen, Harish Nagaraj, Evelyn Tan, 2012 .

Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells

R. Greil, R. Weichselbaum, G. Prendergast, 2011, Molecular Cancer Therapeutics.

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

Supporting Information: Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl- ethoxy)-14,19-dioxa-5,7,26-triaza- tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment o

Harish, J. Wood, Meredith Williams, 2011 .

This information is current as Arthritis and c-Fms for the Treatment of Rheumatoid SB 1578 , a Novel Inhibitor of JAK 2 , FLT 3 , Dymock and

B. Madan, K. Goh, K. Ethirajulu, 2012 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.